MIS416

BIOLOGICAL2 trials

Sponsors

Innate Immunotherapeutics

Conditions

Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis

Phase 1

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

CompletedNCT01191996

Innate ImmunotherapeuticsPrimary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Start: 2010-08-31End: 2012-11-30Updated: 2012-12-07

Phase 2

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

CompletedNCT02228213

Innate ImmunotherapeuticsSecondary Progressive Multiple Sclerosis

Start: 2014-10-31End: 2017-06-30Updated: 2017-07-14

Related Papers

Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.

2017-11-163 citations

Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis

Multiple Sclerosis Journal - Experimental Translational and Clinical2015-05-1215 citations